Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2
Specific aim 1: To test the hypothesis that supplementation of 3.5g EPA+DHA will increase
the acute net fractional muscle protein synthesis more in COPD patients as compared to
healthy controls in response to a high quality protein supplement.
Specific aim 2: To test the hypothesis that 3.5g/day EPA+DHA for 4 consecutive weeks induces
a higher increase in net fractional muscle protein synthesis in response to a high quality
protein supplement as compared to 2g/day EPA+DHA in COPD patients.
Therefore, to answer the specific aims in this study only the COPD subjects will undergo a
4-week intervention period.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
Fractional muscle protein synthesis and breakdown rate (FSR and FBR) of mixed muscle protein (%/h) and net fractional muscle protein synthesis (nFSR = FSR - FBR)
On the study days the primary outcome measure is determined acutely before and after 4 hours of feeding and after intake of either the 3.5 g EPA+DHA, a placebo or 2.0 g EPA+DHA (last category only applicable to COPD group). After study day 1 COPD patients undergo a 4-week intervention period of daily EPA+DHA or placebo supplementation and on their return visit (2nd study day) the primary outcome measure is determined again.
Acutely before and after 4 hours of feeding and the change after 4 weeks of EPA+DHA or placebo supplementation
Marielle Engelen, PhD
Texas A&M University
United States: Institutional Review Board
|Texas A&M University||College Station, Texas 77843|